Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Jul 2023: Trial registered, NCT05941507
  2. 5 Oct 2023: Trial started, NCT05941507

The trials

NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
300 planned
Started
5 Oct 2023
Primary completion
Jan 2027
Arms
LCB84 + anti-PD-1
Results
None posted
  1. 12 Jul 2023: Trial registered
  2. 5 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.